Edwards Lifesciences Corp VP Patrick B. Verguet Sells 5,000 Shares (EW)
Edwards Lifesciences Corp (NYSE:EW) VP Patrick B. Verguet unloaded 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $92.00, for a total value of $460,000.00. Following the transaction, the vice president now directly owns 49,053 shares of the company’s stock, valued at approximately $4,512,876. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on EW. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $90.00.
Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 1.91% during mid-day trading on Friday, hitting $91.97. The stock had a trading volume of 1,899,876 shares. Edwards Lifesciences Corp has a 52-week low of $60.62 and a 52-week high of $94.50. The stock has a 50-day moving average of $85.98 and a 200-day moving average of $77.78. The company has a market cap of $9.712 billion and a P/E ratio of 13.02.
Edwards Lifesciences Corp (NYSE:EW) last announced its earnings results on Tuesday, July 29th. The company reported $0.88 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter last year, the company posted $0.82 earnings per share. Edwards Lifesciences Corp’s revenue was up 11.2% compared to the same quarter last year. On average, analysts predict that Edwards Lifesciences Corp will post $3.28 earnings per share for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.